CTE Sessions at EANM’13

EANM’13 – Mini Course II

October 20, 2013, 15:45 – 16:45
Technologists Perspective in Radionuclide Therapy

Chairpersons: C. Pestean (Cluj), M. Hinterreiter (Linz)

G. Flux (Sutton Surrey):
Dosimetry in Radionuclide Therapy
E. Mantel (Philadelphia):
Radiopharmaceuticals in Radionuclide Therapy

Educational objectives:

  1. To explain the role of nuclear medicine technologists in radionuclide therapy
  2. To find information about role of dosimetry in radionuclide therapy
  3. To learn how dosimetry helps clinicians to optimise radionuclide therapy in order to have the best therapeutic results
  4. To make an overview of radiopharmaceuticals used for therapeutic purposes in nuclear medicine
  5. To discover useful aspects about radiopharmacy related to radionuclide therapy


Radionuclide therapy involves a multidisciplinary team. The decision and the responsibility to perform this type of therapy lie on the shoulders of the clinician, who is the leader of the medical team. Besides clinical aspects, there are many other aspects that play an important role. Radionuclide therapy is a complex procedure where aspects related to radiopharmacy and dosimetry play a crucial role not only in the success of the therapy, but also for the patient’s safety.
Many pathologies benefit from this therapeutic alternative, with good results and minimal toxicity for the patient. It is well known that for therapeutic purposes, beta particles are used to deposit energy in target tissues and to produce damages at cellular level. Besides clinical aspects, there are many other important aspects when the decision to perform this therapeutic procedure is taken: which are the available radiopharmaceuticals, how they will uptake in target tissues, what energy and what activity would be suitable for each situation. For this, dosimetry and radiopharmacy give responses to the clinicians and allow them to make the best choice.

Key Words:

Dosimetry, Adiopharmaceuticals, Radionuclide Therapy, Nuclear Medicine Technologists

This website uses cookies. Learn more